Iron chelation beyond transfusion iron overload

American Journal of Hematology

Volumn 82, Issue 12 SUPPL., 2007, Pages 1142-1146

  Pietrangelo, Antonello ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; INTERFERON; RIBAVIRIN;

BLOOD TRANSFUSION; CELL DAMAGE; CELL DEATH; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; FRIEDREICH ATAXIA; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHLEBOTOMY; PRIORITY JOURNAL; THALASSEMIA; VIRUS HEPATITIS;

BIOLOGICAL TRANSPORT; BLOOD TRANSFUSION; FATTY LIVER; FRIEDREICH ATAXIA; HEMOCHROMATOSIS; HUMANS; IRON; IRON OVERLOAD; ORGANELLES;

EID: 36849075284     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21101     Document Type: Conference Paper

References (65)

1. Pietrangelo A. Hemochromatosis: An endocrine liver disease. Hepatology 2007;46:1291-1301.
2. Madani TA, Bormanis J. Reversible severe hereditary hemochromatotic cardiomyopathy. Can J Cardiol 1997;13:391-394.
3. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003;123:952-953.
4. Barton JC, Sublett S, Boyd GL. Management of hemochromatosis in a Jehovah's Witness. Am J Hematol 2005;78:83.
5. Polo-Romero FJ. Intramuscular deferoxamine in hereditary hemochromatosis. Am J Hematol 2006;81:225-226.
6. Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007;109:362-364.
7. Imbert-Bismut F, Charlotte F, Turlin B, et al. Low hepatic iron concentration: Evaluation of two complementary methods, colorimetric assay and iron histological scoring. J Clin Pathol 1999;52:430-434.
8. Guillygomarc'h A, Mendler MH, Moirand R, et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001;35:344-349.
9. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509-1523.
10. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
11. Piperno A, D'Alba R, Fargion S, et al. Liver iron concentration in chronic viral hepatitis: A study of 98 patients. Eur J Gastroenterol Hepatol 1995;7:1203-1208.
12. Ludwig J, Hashimoto E, Porayko MK, et al. Hemosiderosis in cirrhosis: A study of 447 native livers. Gastroenterology 1997;112:882-888.
13. Paradis V, Mathurin P, Kollinger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathol 1997;50:401-406.
14. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994;41:343-348.
15. Bonkovsky HL, Troy N, McNeal K, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002;37:848-854.
16. Thorburn D, Morris AJ, Stanley AJ, Mills PR. Underdiagnosis of hereditary haemochromatosis: Reflects lack of clinical not biochemical penetrance. Gut 2003;52:455.
17. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
18. Barry M, Cartei G, Sherlock S. Measurement of iron stores in cirrhosis using diethylenetriamine penta-acetic acid. Gut 1970;11:899-904.
19. Brissot P, Wright TL, Ma WL, Weisiger RA. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985;76:1463-1470.
20. Sturrock A, Alexander J, Lamb J, et al. Characterization of a transferrin-independent uptake system for iron in HeLa cells. J Biol Chem 1990;265:3139-3145.
21. Fleming RE, Migas MC, Holden CC, et al. Transferrin receptor 2: Continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci USA 2000;97:2214-2219.
22. Cardoso EM, Duarte MA, Ribeiro E, et al. A study of some hepatic immunological markers, iron load, and virus genotype in chronic hepatitis C. J Hepatol 2004;41:319-326.
23. Bennett MJ, Lebron JA, Bjorkman PJ. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature 2000;403:46-53.
24. Ehrlich R, Lemonnier FA. HFE - A novel nonclassical class I molecule that is involved in iron metabolism. Immunity 2000;13:585-588.
25. Weiss G, Umlauft F, Urbanek M, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999;180:1452-1458.
26. Theurl I, Zoller H, Obrist P, et al. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 2004;190:819-825.
27. Fillebeen C, Rivas-Estilla AM, Bisaillon M, et al. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem 2005;280:9049-9057.
28. Alexander J, Tung BY, Croghan A, Kowdley KV. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress, and serum liver enzymes in chronic hepatitis C: Results of a pilot study. Liver Int 2007;27:268-273.
29. Kawamura Y, Akuta N, Sezaki H, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 2005;40:901-906.
30. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001;61:8697-8702.
31. Rulyak SJ, Eng SC, Patel K, et al. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005;100:332-337.
32. Bonkovsky HL, Naishadham D, Lambrecht RW, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-1451.
33. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: An overview. J Gastroenterol Hepatol 2002;17:1136-1143.
34. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17(suppl):S186-S190.
35. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
36. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes Care 2003;26:3153-3159.
37. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002;51:3120-3127.
38. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: The Strong Heart Study. Diabetes Care 2003;26:861-867.
39. Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-1257.
40. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-939.
41. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003;5:18-25.
42. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-850.
43. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000;355:2181-2182.
44. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-2455.
45. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-187.
46. Fernández-Real JM, Peñarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: Effects on vascular reactivity. Diabetes Care 2002;25:2249-2255.
47. Piperno A, Vergani A, Salvioni A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004;24:471-476.
48. Sumida Y, Kanemasa K, Fukumoto K, et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res 2006;36:315-321.
49. Fargion S, Dongiovanni P, Guzzo A, et al. Iron and insulin resistance. Aliment Pharmacol Ther 2005;22(suppl 2):61-63.
50. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004;32:131-138.
51. Campuzano V, Montermini L, Molto M D, et al. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
52. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. Selective iron chelation in Friedreich ataxia: Biologic and clinical implications. Blood 2007;110:401-408.
53. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. Br J Pharmacol 2005;146:1041-1059.
54. Sofie E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
55. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
56. Hirsch EC, Brandel JP, Galle P, et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis. J Neurochem 1991;56:446-451.
57. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32 (Suppl):S2-S9.
58. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
59. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferoxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-1308.
60. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006;103:14901-14906.
61. Le NT, Richardson DR. The role of iron in cell cycle progression and the pro-liferation of neoplastic cells. Biochim Biophys Acta 2002;1603:31-46.
62. Buss JL, Greene BT, Turner J, et al. Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004;4:1623-1635.
63. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547-583.
64. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997;89:3025-3038.
65. Brodie C, Siriwardana G, Lucas J, et al. Neuroblastoma sensitivity to growth inhibition by deferoxamine: Evidence for a block in G1 phase of the cell cycle. Cancer Res 1993;53:3968-3975.